Researchers develop a novel and safe treatment for two autoimmune diseases.... Read More
The project uses preclinical seizure models and neuroscience techniques to help develop new antiepileptic agents. Some 800-1000 novel compounds per year are evaluated against conventional drugs for anticonvulsant efficacy and potency, neurotoxicity, effect on liver function, and mechanism of action. Promising compounds, which exhibit a high level and/or unusual spectrum of anticonvulsant activity with superior therapeutic potential, are selected for detailed toxicology studies and subsequent clinical trials in epileptic patients. The project has been continually funded since 1975 and every new anticonvulsant introduced to clinical use in the USA during the past 40 years has been evaluated in this research program.
The program is an integral part of the Department of Pharmacology and Toxicology and, as such, provides a site for research training of undergraduate students, departmental graduate students and postdoctoral fellows. Faculty aligned with the program also provide instruction to professional students in the College of Pharmacy and the School of Medicine.
ADD's College of Pharmacy’s Program Awarded $19.5M Contract Renewal To Identify Compounds for Treating Therapy-Resistant Epilepsy
... Read More
... Read More
University of Utah Health College of Pharmacy has received $2.6 million in contract funding from the National Institutes of Health to evaluate new small molecules to treat pain as part of the Helping to End Addiction Long-term (HEAL) Initiative. ... Read More
Our students traveled to Blue Mountain Hospital located in Blanding, Utah for their Rural Outreach Trip.... Read More
A research collaboration agreement between SCM Lifescience and CSTEC@Utah took place on October 10, 2018.... Read More